<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01573169</url>
  </required_header>
  <id_info>
    <org_study_id>PREVENTIHS</org_study_id>
    <nct_id>NCT01573169</nct_id>
  </id_info>
  <brief_title>PREvention of VENous Thromboembolism In Hemorrhagic Stroke Patients</brief_title>
  <acronym>PREVENTIHS</acronym>
  <official_title>PREvention of VENous Thromboembolism In Hemorrhagic Stroke Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Of Perugia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Of Perugia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with cerebral hemorrhage (ICH) have a high risk of venous thromboembolism.&#xD;
      Intermittent pneumatic compression combined with elastic stockings have been shown to be&#xD;
      superior to elastic stockings alone in reducing the rate of asymptomatic deep vein thrombosis&#xD;
      after ICH in a randomized trial (4.7% vs. 15.9%). Graduated compression stockings alone are&#xD;
      ineffective in preventing deep vein thrombosis in patients with ischemic or hemorrhagic&#xD;
      stroke. Less clear is the role of anticoagulation in the prevention of venous thromboembolism&#xD;
      in patients with ICH because the use of anticoagulants may cause an enlargement of the&#xD;
      hematoma. In a multicenter, randomized trial, the investigators will assess the efficacy and&#xD;
      safety of enoxaparin in the prevention of venous thromboembolism in patients with spontaneous&#xD;
      intracerebral hemorrhage. Enoxaparin (40 mg once daily) or standard therapy (graduated&#xD;
      compression stockings and/or intermittent pneumatic compression and/or early mobilization)&#xD;
      will be given subcutaneously for not less than 10 days beginning after 72 hours from stroke&#xD;
      onset.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The trial has been terminated prematurely after the randomization of 73 patients due to a lack&#xD;
    of funding.&#xD;
  </why_stopped>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">March 2020</completion_date>
  <primary_completion_date type="Actual">March 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Symptomatic and Asymptomatic Venous Thromboembolism</measure>
    <time_frame>10 days</time_frame>
    <description>Symptomatic venous thromboembolism (deep venous thrombosis and/or pulmonary embolism) and asymptomatic deep venous thrombosis on ultrasound examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleedings</measure>
    <time_frame>90 days</time_frame>
    <description>symptomatic and asymptomatic intra and extracranial bleedings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>90 days</time_frame>
    <description>mortality of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability</measure>
    <time_frame>90 days</time_frame>
    <description>modified Rankin Scale (mRS) equal to and greater than 3.&#xD;
0 - No symptoms.&#xD;
- No significant disability. Able to carry out all usual activities, despite some symptoms.&#xD;
- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.&#xD;
- Moderate disability. Requires some help, but able to walk unassisted.&#xD;
- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.&#xD;
- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.&#xD;
- Dead.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Hemorrhagic Stroke</condition>
  <condition>Venous Thromboembolism</condition>
  <condition>Deep Venous Thrombosis</condition>
  <arm_group>
    <arm_group_label>low weight molecular heparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>enoxaparin 0.4 ml subcutaneous per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>enoxaparin 0.4 ml sc per day for 10 days started 72 hours after the stroke</description>
    <arm_group_label>low weight molecular heparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization</intervention_name>
    <description>placebo standard therapy</description>
    <arm_group_label>standard therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Intracranial spontaneous hemorrhage on brain CT scan&#xD;
&#xD;
          -  Intracranial hemorrhage during treatment with oral anticoagulants&#xD;
&#xD;
          -  Bedridden patients (item 6 of NIHSS: motor leg points 3 or 4 or severe ataxia for&#xD;
             cerebellar hemorrhage).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  cerebral hemorrhage due to intracranial vascular malformation&#xD;
&#xD;
          -  rebleeding on CT scan after 72 hours from stroke (before randomization)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stroke Unit</name>
      <address>
        <city>Perugia</city>
        <zip>06126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Paciaroni M, Agnelli G, Venti M, Alberti A, Acciarresi M, Caso V. Efficacy and safety of anticoagulants in the prevention of venous thromboembolism in patients with acute cerebral hemorrhage: a meta-analysis of controlled studies. J Thromb Haemost. 2011 May;9(5):893-8. doi: 10.1111/j.1538-7836.2011.04241.x.</citation>
    <PMID>21324058</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 31, 2012</study_first_submitted>
  <study_first_submitted_qc>April 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2012</study_first_posted>
  <results_first_submitted>January 3, 2021</results_first_submitted>
  <results_first_submitted_qc>September 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 10, 2021</results_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Of Perugia</investigator_affiliation>
    <investigator_full_name>Maurizio Paciaroni</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>hemorrhagic stroke</keyword>
  <keyword>venous thromboembolism</keyword>
  <keyword>prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Hemorrhagic Stroke</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 1, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT01573169/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>No wash-out, nor run-in events.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Low Weight Molecular Heparin</title>
          <description>enoxaparin 0.4 ml subcutaneous per day&#xD;
Enoxaparin: enoxaparin 0.4 ml sc per day for 10 days started 72 hours after the stroke</description>
        </group>
        <group group_id="P2">
          <title>Standard Therapy</title>
          <description>Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization&#xD;
Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization: placebo standard therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Weight Molecular Heparin</title>
          <description>enoxaparin 0.4 ml subcutaneous per day&#xD;
Enoxaparin: enoxaparin 0.4 ml sc per day for 10 days started 72 hours after the stroke</description>
        </group>
        <group group_id="B2">
          <title>Standard Therapy</title>
          <description>Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization&#xD;
Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization: placebo standard therapy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="73"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.4" spread="13.7"/>
                    <measurement group_id="B2" value="71.5" spread="11.6"/>
                    <measurement group_id="B3" value="70.9" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Obesity</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Symptomatic and Asymptomatic Venous Thromboembolism</title>
        <description>Symptomatic venous thromboembolism (deep venous thrombosis and/or pulmonary embolism) and asymptomatic deep venous thrombosis on ultrasound examination</description>
        <time_frame>10 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Weight Molecular Heparin</title>
            <description>enoxaparin 0.4 ml subcutaneous per day&#xD;
Enoxaparin: enoxaparin 0.4 ml sc per day for 10 days started 72 hours after the stroke</description>
          </group>
          <group group_id="O2">
            <title>Standard Therapy</title>
            <description>Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization&#xD;
Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization: placebo standard therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Symptomatic and Asymptomatic Venous Thromboembolism</title>
          <description>Symptomatic venous thromboembolism (deep venous thrombosis and/or pulmonary embolism) and asymptomatic deep venous thrombosis on ultrasound examination</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleedings</title>
        <description>symptomatic and asymptomatic intra and extracranial bleedings</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Weight Molecular Heparin</title>
            <description>enoxaparin 0.4 ml subcutaneous per day&#xD;
Enoxaparin: enoxaparin 0.4 ml sc per day for 10 days started 72 hours after the stroke</description>
          </group>
          <group group_id="O2">
            <title>Standard Therapy</title>
            <description>Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization&#xD;
Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization: placebo standard therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Bleedings</title>
          <description>symptomatic and asymptomatic intra and extracranial bleedings</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <description>mortality of any cause</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Weight Molecular Heparin</title>
            <description>enoxaparin 0.4 ml subcutaneous per day&#xD;
Enoxaparin: enoxaparin 0.4 ml sc per day for 10 days started 72 hours after the stroke</description>
          </group>
          <group group_id="O2">
            <title>Standard Therapy</title>
            <description>Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization&#xD;
Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization: placebo standard therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>mortality of any cause</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disability</title>
        <description>modified Rankin Scale (mRS) equal to and greater than 3.&#xD;
0 - No symptoms.&#xD;
- No significant disability. Able to carry out all usual activities, despite some symptoms.&#xD;
- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.&#xD;
- Moderate disability. Requires some help, but able to walk unassisted.&#xD;
- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.&#xD;
- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.&#xD;
- Dead.</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Weight Molecular Heparin</title>
            <description>enoxaparin 0.4 ml subcutaneous per day&#xD;
Enoxaparin: enoxaparin 0.4 ml sc per day for 10 days started 72 hours after the stroke</description>
          </group>
          <group group_id="O2">
            <title>Standard Therapy</title>
            <description>Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization&#xD;
Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization: placebo standard therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Disability</title>
          <description>modified Rankin Scale (mRS) equal to and greater than 3.&#xD;
0 - No symptoms.&#xD;
- No significant disability. Able to carry out all usual activities, despite some symptoms.&#xD;
- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.&#xD;
- Moderate disability. Requires some help, but able to walk unassisted.&#xD;
- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.&#xD;
- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.&#xD;
- Dead.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Low Weight Molecular Heparin</title>
          <description>enoxaparin 0.4 ml subcutaneous per day&#xD;
Enoxaparin: enoxaparin 0.4 ml sc per day for 10 days started 72 hours after the stroke</description>
        </group>
        <group group_id="E2">
          <title>Standard Therapy</title>
          <description>Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization&#xD;
Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization: placebo standard therapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intracranial bleedings</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>extracranial bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Maurizio Paciaroni</name_or_title>
      <organization>Stroke Unit and Division of Internal and Cardiovascular Medicine University of Perugia, Santa Maria della Misericordia Hospital</organization>
      <phone>+390755786424</phone>
      <email>maurizio.paciaroni@unipg.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

